Icotinib Hydrochloride in Treating Patients With Advanced Cancers - Trial NCT02033148
Access comprehensive clinical trial information for NCT02033148 through Pure Global AI's free database. This Phase 1 trial is sponsored by Roswell Park Cancer Institute and is currently Withdrawn. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 0 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Roswell Park Cancer Institute
Timeline & Enrollment
Phase 1
Aug 01, 2014
N/A
Primary Outcome
MTD of icotinib hydrochloride, defined as the highest dose level at which = 1 of 6 evaluable patients experiences a dose-limiting toxicity, as graded using NCI CTCAE version 4.0,PK parameters of icotinib hydrochloride
Summary
This phase I trial studies the side effects and best dose of icotinib hydrochloride in
 treating patients with advanced cancers. Icotinib hydrochloride may stop the growth of tumor
 cells by blocking some of the enzymes needed for cell growth.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02033148
Non-Device Trial